Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Nov 17;9(11):e112303.
doi: 10.1371/journal.pone.0112303. eCollection 2014.

Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa

Erica Maxine Lazarus  1 , Kennedy Otwombe  1 , Tania Adonis  2 , Elaine Sebastian  3 , Glenda Gray  1 , Nicole Grunenberg  4 , Surita Roux  3 , Gavin Churchyard  2 , Craig Innes  2 , Fatima Laher  1
Affiliations
Clinical Trial

Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa

Erica Maxine Lazarus et al. PLoS One. .

Abstract

Because sexual transmission of HIV occurs across mucosal membranes, understanding the immune responses of the genital mucosa to vaccines may contribute knowledge to finding an effective candidate HIV vaccine. We describe the uptake of rectal secretion, cervical secretion and seminal mucosal secretion sampling amongst volunteers in a Phase 1b HIV vaccine trial. Age at screening, gender, study site and the designation of the person conducting the informed consent procedure were collected for volunteers who screened for the HVTN 097 study. A total of 211 volunteers (54% female) were screened at three sites in South Africa: Soweto (n = 70, 33%), Cape Town (n = 68, 32%) and Klerksdorp (n = 73, 35%). Overall uptake of optional mucosal sampling amongst trial volunteers was 71% (n = 149). Compared to Cape Town, volunteers from Soweto and Klerksdorp were less likely to consent to sampling (Soweto OR 0.08 CI: 0.03-0.25 p<0.001 and Klerksdorp OR 0.13 CI: 0.04-0.41 p = 0.001). In contrast, volunteers over 25 years of age were 2.39 times more likely to consent than younger volunteers (CI: 1.13-5.08, p = 0.02). Further studies are required to better understand the cultural, demographic and sociobehavioral factors which influence willingness to participate in mucosal sampling in HIV prevention studies.

Trial registration: ClinicalTrials.gov: NCT02109354.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Flow diagram for HVTN 097 screening and enrollment.
See this image and copyright information in PMC

References

    1. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2014) The Gap Report. Available: http://www.unaids.org/en/resources/documents/2014/ Accessed 2014 September 5.
    1. Stover J, Bollinger L, Hecht R, Williams C, Roca E (2007) The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff (Millwood) 26: 1147–1158. - PubMed
    1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209–2220. - PubMed
    1. Iqbal SM, Kaul R (2008) Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol 59: 44–54. - PubMed
    1. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, et al. (1997) HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 3: 1250–1257. - PubMed

Publication types

Associated data